More than 100 Academic, Pharmaceutical and Biotech Companies Select Maxpar Immune Profiling Panels Using CyTOF Technology to Accelerate Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced it has
Delivering automated RNA workflows to significantly reduce cost per sample and hands-on time using microfluidics technology SOUTH SAN FRANCISCO, Calif. , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
SOUTH SAN FRANCISCO, Calif. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report third quarter 2019 financial results on Tuesday,
Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif. , Sept. 24, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Human Proteome Organization (HUPO), an international scientific
SOUTH SAN FRANCISCO, Calif. , Sept. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it has filed new legal action in the United States District Court
Fluidigm Showcases Immuno-Oncology Imaging Innovations at WMIC to Advance Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in highly multiplexed single-scan tissue imaging, today
Mount Sinai selects Fluidigm single-cell microfluidics systems to identify epigenetic changes from environmental agents in study funded by the U.S. Department of Defense SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
SOUTH SAN FRANCISCO, Calif. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that the company’s management will participate in two upcoming investor
